Topic: JPM 2019

While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there are becoming untenable for some.

Deciphera aims to get ripretinib approved first as a fourth- and second-line treatment for GIST, but is not looking for a first-line approval.

Armed with a total of $375 million raised, Orchard will build its own manufacturing site in California, to start running in 2021.

What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.

At JPM, Propeller Health closed its $225 million buyout with ResMed and launched a partnership with Walgreens for in-app prescription refills.

The FDA shutdown is holding up human trials for Aimmune's egg allergy program and may delay approval for its oral immunotherapy for peanut allergy.

We certainly like to offer a full breakfast here at FierceBiotech, especially at the J.P. Morgan Healthcare Conference here in San Francisco.

Since Pavan Cheruvu took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player.

In 2019, Tmunity hopes to share data from its lead T cell programs and announce new solid tumor targets.

Pear Therapeutics posted $64 million in new funding on the heels of an FDA clearance for its prescription software to treat opioid addiction.